AFP and prostate carcinoma: This is the case of the α2,3-SA PSA glycoforms for prostate cancer [72], core fucosylated-AFP glycoforms (AFP-L3) for hepatocellular carcinoma [73] or CA125-STn for ovarian cancer [74].